These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 35906500)
41. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review. Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373 [TBL] [Abstract][Full Text] [Related]
42. Parkinson's Disease Psychosis and the Marketing of Pimavanserin. Daeschler D; Fugh-Berman A Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164 [TBL] [Abstract][Full Text] [Related]
44. Evaluating rates of reporting symptoms of Parkinson's disease psychosis: provider versus targeted questionnaire. Greger J; Aladeen T; Rainka M; Kale A; Capote H Int J Neurosci; 2022 May; 132(5):459-465. PubMed ID: 32910866 [TBL] [Abstract][Full Text] [Related]
45. Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. Dave S; Weintraub D; Aarsland D; Ffytche DH Mov Disord Clin Pract; 2020 Jan; 7(1):32-36. PubMed ID: 31970209 [TBL] [Abstract][Full Text] [Related]
46. [Psychosis in Parkinson's disease]. Rongve A; Auning E; Ehrt U; Arsland D Tidsskr Nor Laegeforen; 2012 Jan; 132(2):155-8. PubMed ID: 22278271 [TBL] [Abstract][Full Text] [Related]
48. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112 [TBL] [Abstract][Full Text] [Related]
49. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963 [TBL] [Abstract][Full Text] [Related]
50. Deconstructing psychosis and misperception symptoms in Parkinson's disease. Nishio Y; Yokoi K; Uchiyama M; Mamiya Y; Watanabe H; Gang M; Baba T; Takeda A; Hirayama K; Mori E J Neurol Neurosurg Psychiatry; 2017 Sep; 88(9):722-729. PubMed ID: 28600444 [TBL] [Abstract][Full Text] [Related]
51. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. Sellers J; Darby RR; Farooque A; Claassen DO Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099 [TBL] [Abstract][Full Text] [Related]
52. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]